The Investigastion of Apoptosis Activation and Cyotoxicity of Melatonin in MCF-7 Cell Culture Through Polimerase Chain Reaction (PCR), MTT Cell Viability Assay and Immunocytochemical Methods

Year 2024, Volume: 10 Issue: 2, 265 - 275, 01.05.2024

Semin Gedikli , Elvan Şahin , Ahmet Özbek , Abdulgani Tatar , Adem Kara , Ahmet Hacımüftüoğlu

https://doi.org/10.53394/akd.1249740

Abstract

Objective: Breast cancer, one of the most common cancer types in the world and in Turkey, ranks first among cancer-related deaths. For this reason, new researches are carried out for the treatment of this disease. We aimed to investigate the relationship of melatonin, a powerful antioxidant, with cancer and its contribution to the solution of cancer.
Methods: In our study, melatonin concentrations in the range of 10 nM–100,000 nM were applied to the MCF-7 cell line to determine the cytotoxic doses and IC50 value of melatonin. After melatonin application, cell viability was determined by MTT analysis and effective doses for melatonin were determined. MCF-7 cells were incubated for 24 hours with 5 concentrations (10, 100, 1000, 10,000 and 100,000 nM) doses of melatonin. Melatonin cytotoxicity, TAS, TOS, apoptotic activity (Bax and p53 immunpositivity) and p53 gene expression levels were examined in all groups.
Results: At the end of the 24-hour incubation, it was determined that melatonin administered to MCF-7 cells inhibited cell proliferation and had a cytotoxic effect, increasing p53 gene expression and Bax protein synthesis. It was determined that Bax and p53 immunopositivity increased in immunocytochemical staining. In addition, melatonin treatment increased TAS and decreased TOS.
Conclusion: These effects show that melatonin induces apoptosis activation due to the increase in p53 gene expression and Bax protein, and thus may be an adjunctive agent that can be used in cancer treatment.

Keywords

Apoptosis, Bax, Breast cancer, Melatonin, p53

Project Number

-

Melatoninin MCF-7 Hücre Kültüründeki Apoptoz Aktivasyonunun ve Sitotoksisitesinin Polimeraz Zincir Reaksiyonu (PCR), MTT Hücre Canlılık Testi ve İmmunsitokimya Yöntemleriyle Araştırılması

Abstract

Amaç: Dünyada ve Türkiye'de en sık görülen kanser türlerinden biri olan meme kanseri, kanser nedenli ölüm oranları arasında ilk sıralarda yer almaktadır. Bu nedenle bu hastalığın tedavisine yönelik yeni araştırmalar yapılmaktadır. Biz de güçlü bir antioksidan olan melatoninin kanserle ilişkisini ve kanser hastalığının çözümüne katkısını araştırmayı amaçladık.
Yöntemler: Çalışmamızda melatoninin sitotoksik dozlarını ve IC50 değerini belirleyebilmek için MCF-7 hücre hattına 10 nM–100.000 nM aralığında melatonin konsantrasyonları uygulandı. Melatonin uygulamasının ardından MTT analizi ile hücre canlılığı tespiti yapıldı ve melatonin için etkin dozlar belirlendi. MCF-7 hücreleri, 5 konsantrasyon (10, 100, 1000, 10.000 ve 100.000 nM) melatonin dozu ile 24 saat inkübasyon işlemine tabi tutuldu. Tüm gruplarda melatonin sitotoksisitesi, TAS, TOS, apoptotik aktivite (Bax ve p53 immünpozitifliği) ve p53 geninin ekspresyon düzeyleri incelendi.
Bulgular: 24 saatlik inkübasyon sonunda MCF-7 hücrelerine uygulanan melatoninin hücre proliferasyonunu inhibe ederek sitotoksik etki yaptığı, p53 gen ekspresyonunu ve Bax protein sentezini artırdığı tespit edildi. İmmünsitokimyasal boyamada Bax ve p53 immünpozitifliğinin arttığı belirlendi. Ayrıca melatonin tedavisi TAS'ı artırıp TOS'u azalttı.
Sonuç: Bu etkiler, melatoninin p53 gen ekspresyonu ve Bax proteinindeki artışa bağlı olarak apoptoz aktivasyonunu indüklediğini ve dolayısıyla kanser tedavisinde kullanılabilecek yardımcı bir ajan olabileceğini göstermektedir.

Keywords

Apoptoz, Bax, Meme Kanseri, Melatonin, p53

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1- Kutlu R, Demirbaş N, Börüban MC, Güler T. Sigara içmeye atfedilebilen kanser türleri ve sosyodemografik özellikleri. Turk Onkol Derg 2014; 29(3): 81-8.
• 2- Yokuş B, Çakır DÜ. Kanser biyokimyası. Dicle Univ Ver Fak Derg 2012; 1: 7-18.
• 3- Alıcı S, İzmirli M, Doğan E. Yüzüncü Yıl Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı’na başvuran kanser hastalarının epidemiyolojik değerlendirilmesi. Türk Onkol Derg 2006; 21:87-97.
• 4- The Global Cancer Observatory (GCO). https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf (Erişim tarihi: 20.05.2022)
• 5- Yazıcı O, Özdemir N. Meme kanserinde epidemiyolojik veriler, risk faktörleri, risk azaltıcı yaklaşımlar. T Klin Tıbbi Onkoloji-Özel Konular 2018; 11(1): 1-7.
• 6- Sofi MS, Sateesh MK, Bashir M, Ganie MA, Nabi S. Chemopreventive and anti-breast cancer activity of compounds isolated from leaves of Abrus precatorius L. 3 Biotech 2018; 8(8): 371.
• 7- Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today 2010; 15(19-20): 842-50.
• 8- Şimşek F, Sevinç İ, Müftüoğlu S, Özbilgin K, Vatansever S, Tuğlu İ. Meme kanseri hücre hatlarında propranolol ve paklitakselin anjiyogenez üzerine etkisi. Cukurova Med J 2019; 44(1): 144-53.
• 9- Karaman A. Mide kanserinde p53 tümör supresör geninin rolü. Turkiye Klinikleri J Med Sci 2003; 23: 67-73.
• 10- Özgür MA, Şamlı H, Özgöz A, Solak M, Dilek H. Meme karsinomlarında polimeraz zincir reaksiyonu ve enzim kesimi ile p53 gen mutasyonlarının araştırılması ve dokuda immunohistokimyasal olarak p53 proteininin gösterilmesi. Kocatepe Tıp Derg 2006; 7(1):17-22.
• 11- Yılmaz E, Altunok V. Kanser ve p53 geni. AVKAE Derg 2011; 1: 19-23.
• 12- Coşkun G, Özgür H. Apoptoz ve nekrozun moleküler mekanizması. Ars Kay Tar Derg 2011; 20: 145-58.
• 13- Elmore S. Apoptosis: A review of programmed cell death. Toxıcol Pathol 2007; 35: 495-16.
• 14- Yerlikaya A, Dokudur H. Protein yıkımının önemi. Uludağ Üniv Tıp Fak Derg 2009; 35: 93-9.
• 15- Altunkaynak BZ, Özbek E. Programlanmış hücre ölümü: Apoptoz nedir? Tıp Arast Derg 2008; 6: 93-104.
• 16- Bircan S, Çandır Ö, Kapucuoğlu N, Başpınar Ş. p53, BCL-2, Bax expression in basal cell carcinomas and nontumoral surrounding skin. Turk J Path 2005; 21(3-4): 044-048.
• 17- Ravindra T, Lakshmi NK, Ahuja YR. Melatonin in pathogenesis and therapy of cancer. IJMS 2006; 60: 523-35.
• 18- Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrınol Lett 2001; 22: 45-7.
• 19- Fernández R, Güézmes A, Sánchez-Barceló EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998; 58: 4383-90.
• 20- Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso- González C, Sánchez-Barceló EJ. Estrogen-signaling pathway: A link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 2006; 30: 118-28.
• 21- Cos S, Sánchez-Barceló EJ. Melatonin and mammary pathological growth. Front Neuroendocrin 2000; 21: 133-70.
• 22- Sánchez-Barceló EJ, Cos S, Fernández R, Mediavilla MD. Melatonin and mammary cancer: a short review. Endocr-Relat Cancer 2003; 10: 153-9.
• 23- Karabekir G, Demircan G, Özdaş Ş. Resveratrolün MCF-7 hücre soyunda apoptotik etkinin araştırılması. FNG & Bilim Tıp Dergisi 2017; 3(1): 27-34.
• 24- Mossman, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicityassays. J. Immunol Methods 1983; 65: 55-63.
• 25- Kalkan Y, Kapakin KAT, Kara A, Atabay T, Karadeniz A, Simsek N, Karakuş E, Can İ, Yıldırım S, Özkanlar S, Şengül E. Protective effect of Panax ginseng against serum biochemical changes and apoptosis in kidney of rats treated with gentamicin sulphate. J Mol Hıstol 2012; 43: 603-613.
• 26- Akman S, Canakci V, Kara A, Tozoglu U, Arabaci T, Dagsuyu İM. Therapeutic effects of alpha lipoic acid and vitamin C on alveolar bone resorption after experimental periodontitis in rats: a biochemical, histochemical, and stereologic study. J Perıodontol 2013; 84: 666-74.
• 27- Huang HL, Hsing HW, Lai TC, Chen YW, Lee TR, Chan HT, Lyu PC, Wu CL, Lu YC, Lin ST, Lin CW, Lai CH, Chang HT, Chou HC, Chan HL. Trypsin-induced proteome alteration during cell subculture in mammalian cells. J Bıomed Scı 2010; 17:36.
• 28- Duijts SFA, Faber MM, Oldenburg HSA, Beurden M, Aaronson NK. Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors-a meta-analysis. Psycho-Oncol 2011; 20: 115-26.
• 29- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
• 30- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. PNAS 2003; 100: 3983-8.
• 31- Andre F, Broglıo K, Pusztaı L, Berrada N, Mackey JR, Nabholtz JM, Chan S, Hortobagyi GN. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized trials. Oncologist 2010; 15: 476-83.
• 32- Muss HB, Case LD, Richards F, White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL, Capizzi RL. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. NEJM., 1991; 325: 1342-8.
• 33- Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, JP Spano, Marsiglia H, Rouzier R, Delaloge S, Spielmann M. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004; 22: 3302-8.
• 34- Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Scı 2003; 94: 15-21.
• 35- Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42-9.
• 36- Türk G. Kemoterapötiklerin erkek üreme sistemi üzerindeki yan etkileri ve koruyucu stratejiler. Marmara Pharm J 2013; 17: 73-92.
• 37- Aitken RJ, Roman SD. Antioxidant systems and oxidative stress in the testes. Oxid Med Cell Longev 2008; 1: 15-24.
• 38- Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60: 1407-26.
• 39- Wenzel U, Nickel A, Daniel H. Melatonin potentiates flavone-induced apoptosis in human colon cancer cells by increasing the level of glycolytic end products. IJC, 2005; 116: 236-42.
• 40- Eck-Enriquez K, Kiefer TL, Spriggs LL, Hill SM. Pathways through which a regimen of melatonin and retinoic acid induces apoptosis in MCF-7 human breast cancer cells. Breast Cancer Res Treat 2000; 61: 229-39.
• 41- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
• 42- Winczyk K, Pawlikowski M, Lawnicka H, Kunert-Radek J, Spadoni G, Tarzia G, Karasek M. Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl) methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo. Neuro Endocrinol. Lett 2002; 23: 50-54.
• 43- Vijayalaxmi B, Thomas CR, Reiter RJ, Herman TS. Melatonin: From basic research to cancer treatment clinics. J Clin Oncol 2002; 20: 2575-2601.
• 44- Brömme HJ, Mörke W, Peschke E, Ebelt H, Peschke D. Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. J Pineal Res 2000; 29: 201-208.
• 45- Ebelt H, Peschke D, Brömme HJ, Mörke W, Blume R, Peschke E. Influence of melatonin on free radical-induced changes in rat pancreatic beta-cells in vitro. J Pineal Res 2000; 28: 65-72.
• 46- Gitto E, Tan DX, Reiter RJ, Karbownik M, Manchester LC, Cuzzocrea S, Fulia F, Barberi I. Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol 2001; 53: 1393-1401.
• 47- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
• 48- Alley MC, Scudiere DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48: 589-601.
• 49- Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-942.
• 50- Abe K, Matsuki N. Measurement of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction activity and lactate dehydrogenase release using MTT. Neurosci Res 2000; 38: 325-9.
• 51- Jung-Hynes B, Schmit TL, Reagan- Shaw SR, Siddiqui IA, Mukhtar H, Ahmad N. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res 2011; 50: 140-9.
• 52- Cos S, Blask DE, Lemus-Wilson A, Hill AB. Effects of melatonin on the cell cycle kinetics and "estrogen-rescue" of MCF-7 human breast cancer cells in culture. J Pineal Res 1991; 10: 36-42.
• 53- Rodriguez C, Mayo JC, Sainz RM, Antolín I, Herrera F, Martín V, Reiter RJ. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9.
• 54- Karbownik M, Lewinski A, Reiter RJ. Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol 2001; 33: 735-53.
• 55- Matѐs JM. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 2000; 153: 83-104.
• 56- Reiter RJ. Aging and oxygen toxicity: relation to changes in melatonin. Age 1997; 20: 201-13.
• 57- Reiter RJ. Oxidaive damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998; 56: 359-84.
• 58- Reiter RJ, Tan DX, Qi W, Manchester LC, Karbownik M, Calvo JR. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept 2000; 9: 160-71.
• 59- Albarrán MT, López-Burillo S, Pablos MI, Reiter RJ, Agapito MT. Endogenous rhythms of melatonin, total antioxidant status and superoxide dismutase activity in several tissues of chick and their inhibition by light. J Pineal Res 2001; 30: 227-33.
• 60- Sırmatel F, Duygu F, Çelik H, Selek Ş, Sırmatel Ö, Gürsoy B, Eriş FN. Kronik viral hepatit olgularında total oksidatif seviye ve total antioksidan kapasitenin değerlendirilmesi. Klimik Derg 2009; 22: 92-6.
• 61- Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 1998; 3: 49-61.
• 62- Clemons M, Goss P. Estrogen and the risk of breast cancer. NEJM 2001; 344: 276-85.
• 63- Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez-Campa C, González A, Alonso- González C. Melatonin–estrogen interactions in breast cancer. J Pineal Res 38: 217-22.
• 64- Kiefer T, Ram PT, Yuan L, Hill SM. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 2002; 71: 37-45.
• 65- Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L. Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther 2009; 8: 337-46.
• 66- Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985; 45: 584-90.
• 67- Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
• 68- Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. PNAS 1995; 92: 8493-7.
• 69- Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21: 2613-22.
• 70- Janusa F, Albrechtsena N, Dornreitera I, Wiesmüller L, Grosseb F, Depperta W. The dual role model for p53 in maintaining genomic integrity. Cell Mol Life Sci 1999; 55: 12-27.
• 71- Asker C, Wiman KG, Selivanova G. p53-Induced apoptosis as a safeguard against cancer. Biochem Biophys Res Commun 1999; 265: 1-6.
• 72- Schernhammer ES, Schulmeister K. Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? Br J Cancer 2004; 90: 941-3.
• 73- Dillon DC, Easley SE, Asch BB, Cheney RT, Brydon L, Jockers R, Winston JS, Brooks JS, Hurd T, Asch HL. Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol 2002; 118: 451-8.
• 74- Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res 2000; 28: 227-33.
• 75- Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC, Murph y E. The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 1999; 26: 129-36.
• 76- Mocchegiani E, Perissin L, Santarelli L, Tibaldi A, Zorzet S, Rapozzi V, Giacconi R, Bulian D, Giraldi T. Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2. Int J Immunopharmacol 1999; 21: 27-46.
• 77- Gilad E, Laufer M, Matzkin H, Zisapel N. Melatonin receptors in PC3 human prostate tumor cells. J Pineal Res 1999; 26: 211-20.
• 78- Anisimov VN, Popovich IG, Shtylik AV, Zabezhinski MA, Ben-Huh H, Gurevich P, Berman V, Tendler Y, Zusman I. Melatonin and colon carcinogenesis III. Effect of melatonin on proliferative activity and apoptosis in colon mucosa and colon tumors induced by l,2-dimethylhydrazine in rats. Exp Toxicol Pathol 2000; 52: 71-6.
• 79- Hilde E.van Gijssel, Rob P.M.van Gijlswijk, Richard R.de Haas, C Stark, Mulder GJ, Meerman JHN. Immunohistochemical visualization of wild-type p53 protein in paraffin-embedded rat liver using tyramide amplification: Zonal hepatic distribution of p53 protein after N-hydroxy-2-acetylaminofluorene administration. Carcinogenesis 1998; 19: 219-22.
• 80- Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N, Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002; 277: 21843-50.
• 81- Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Lüscher TF, Fujii T. Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem 1999; 274: 37461-6.
• 82- Naumovski L, Clean ML. Bcl-2 Inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells. Blood 1994; 83: 2261-2267.
• 83- Leja-Szpak A, Jaworek J, Pierzchalski P, Reiter RJ. Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 2010; 49: 248-55.
• 84- Joo SS, Yoo YM. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 2009; 47: 8-14.
• 85- Jang SS, Kim WD, Park WY. Melatonin exerts differential actions on X-ray radiation-induced apoptosis in normal mice splenocytes and Jurkat leukemia cells. J Pineal Res 2009; 47: 147-55.
• 86- Cucina A, Proietti S, D’Anselmi F, Coluccia P, Dinicola S, Frati L, Bizzarri M. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res 2009; 46: 172-80.